This article was first published by The Times of Israel and is re-posted with permission.
An Israeli drugmaker says a therapy it is developing reduced deaths among patients battling serious bouts of COVID-19 by 70 percent, and nearly halved hospitalization length in a small trial.
A clinical study for MesenCure, conducted in Israel, involved 50 patients hospitalized in serious condition, and a similar size control group that received the best standard of care without the drug.
Haifa-based Bonus BioGroup, which developed the drug, reported that out of the first 30 patients who received the therapy, two died, representing 6.7 percent of the group, and the average hospitalization of those treated was 9.4 days. A third of the patients who received the drug were discharged from the hospital as the five-day course of treatment ended.
To read the full article, click here: